StarFive’s RISC-V Based JH-7110 Intelligent Vision Processing Platform Adopted VeriSilicon’s Display Processor IP
21.3.2024 01:00:00 CET | Business Wire | Press Release
VeriSilicon (688521.SH) today announced the successful integration of its Display Processor IP DC8200 into StarFive’s JH-7110 RISC-V mass production SoC. With high performance, low power consumption and high security features, this collaboration delivers a complete intelligent vision processing platform solution tailored for diverse applications including cloud computing, industrial control, Network Attached Storage (NAS), tablets, and Human-Machine Interface (HMI).
VeriSilicon’s DC8200 IP supports advanced image quality enhancements, enabling user premium visual experiences. It can be configured to provide optimal solutions for target applications. By integrating VeriSilicon’s proprietary compression technology, DC8200 significantly reduces DDR bandwidth, thereby enhancing overall efficiency. Moreover, DC8200 supports dual operating systems and collaborates with the RISC-V CPU to meet diverse product requirements.
Additionally, DC8200 can form robust subsystems through seamless integration with VeriSilicon’s video/image processing IPs, delivering immersive experience to end users with crisp edge, fine detail enhancement, and rich color.
Thomas Xu, CEO of StarFive, said, “Our RISC-V based JH-7110 SoC performs a variety of complex video image processing and intelligent visual computing tasks, meeting the diverse real-time visual processing needs at the edge. VeriSilicon’s display processor IP offers high visual quality with low power consumption. We are committed to advancing innovation based on RISC-V technology. With companion pixel processing IP available through our IP partners, RISC-V based products can be brought to market at an accelerated pace.”
“Starfive’s JH-7110 is a leading RISC-V based intelligent vision processor equipped with advanced smart display capabilities. In the smart display domain, there exists a strong market demand for sophisticated image quality enhancement technologies,” said Wei-Jin Dai, Executive VP and GM of IP Division at VeriSilicon. “The Display Processor IP, as part of our extensive Glass-to-Glass (from camera-in to display-out) intelligent pixel processing IP portfolio, is engineered to deliver superior image quality while ensuring low power consumption. The integration of our DC8200 with JH-7110 is instrumental in driving the performance of numerous screens within the RISC-V ecosystem.”
About StarFive
Founded in 2018, StarFive is a Chinese local high-tech company with independent intellectual properties. As the leader of the RISC-V software and hardware ecosystem in China, StarFive provides world-leading products and solutions on RISC-V covering IP, SoC, development boards, etc.
StarFive has independently developed RISC-V CPU IPs and NoC IPs, of which Dubhe-90 is the max performance commercial RISC-V CPU IP in China, and StarLink-700 is the first mesh coherent interconnect fabric IP in China. Based on these core IPs, StarFive can also provide customers with RISC-V subsystem IP solutions for multi-core, big.little core, and manycore. These products can be applied in high-performance and energy-efficient scenarios, including industrial control, desktop computing, mobile, network communication, machine learning, artificial intelligence, and data centers. Meanwhile, StarFive has also delivered JH-7110 SoC, the world’s first high-performance RISC-V multimedia processor for mass-production. For more information, please visit https://www.starfivetech.com
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: http://www.verisilicon.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240319671767/en/
Contact information
Media Contact: press@verisilicon.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom